Sept. 29, 2013
/PRNewswire/ -- Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress (ECC 2013), which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment.
Molecular Profiling in Carcinoma of Unknown Primary (CUP)
Results from the study, 'Biotheranostic profiling of CUP: paradigm shift in the management of CUP', show that molecular profiling may positively influence patient outcomes when the primary site of the patient's tumor is unknown by providing oncologists with critical new information to help them select optimal treatment.
Using a variety of profiling technologies to assess the biomarkers associated with the potential for drug response, the researchers were able to find targets for which there are existing cancer drugs in 77% of the tumors profiled.
, MD, DSc, Medical Director, Caris Life Sciences and an Adjunct Professor of Pathology,
School of Medicine, reported that his team's research has shown that investigating the biology of a CUP patient's tumor is a potentially effective way of developing an actionable treatment plan for most patients.
"Previous attempts to characterize cancer of unknown primary (CUP) have only managed to provide a statistical likelihood of a potential primary organ site, and for the most part have not addressed the question of which treatments are likely to be effective," said Dr. Gatalica. "We set out to do just that in a large group of over 1,350 CUP patients. This is the largest group to date to have their tumor biomarker profiles characterized."
"We believe that our research, based on the Caris Molecular Intelligence™ service, signals a paradigm shift in the treatment of CUP," added Dr. Gatalica. "With this strategy, physicians can build a treatment plan based on changes in cancer cells which are known to be associated with the potential for benefit from specific drugs. We could be looking at the evolution of a new standard of care for these patients who badly need new options."